Protective Role of Antibiotics (Anisomycin and Puromycin) Against Snake Venom Acetylcholinesterase (AChE)

Alzheimer’s disease (AD) a key health problem chiefly in industrialized countries is characterize by memory loss in older persons. Treatments for AD include psychotropic mediators, disease-modifying managements, psychosocial interventions, and especially inhibition of cholinesterase (AChE) enzyme that will block the hydrolysis of a neurotransmitter acetylcholine (ACh). In the current study, it is reported for the first time that Anisomycine and Puromycin inhibit the activity of the AChE enzyme of krait venom. The results revealed that both Anisomycine (0.8–2.4 mM) and Puromycin (36.8–73.6 µM) exhibited AChE in a dose-dependent procedure. A kinetic study using the plot of Lineweaver Burk showed that both Anisomycine and Puromycin caused a competitive type of inhibition against AChE. The antibiotics (Anisomycin and Puromycin) compete with ACh for binding to the enzyme AChE active site. The Km of venom AChE for Anisomycin (0.8–1.6 mM) increased from 64 to 161% and the Vmax remains constant while for Puromycin (36.8–73.6 µM) the Km increased from 34 to 180% and did not affect the Vmax. The calculated IC50 for Anisomycine was found to be 1.4 mM while for Puromycine it was found to be 36.5 µM. In comparison, Puromycine has a more potent inhibitory effect than Anisomycine. It is concluded, that Anisomycin and Puromycin may possess the anti-AChE ability against Krait snake venom acetylcholinesterase. [ABSTRACT FROM AUTHOR]